Spondyloarthritis
101
12
17
49
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.0%
5 terminated out of 101 trials
90.7%
+4.2% vs benchmark
20%
20 trials in Phase 3/4
18%
9 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (101)
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism
Pregnancy and Medically Assisted Conception in Rare Diseases
Move Your Spondyl " Better Live Its Rheumatism With the Physical Activity "
Biobank for Inflammatory Chronic Diseases and Osteoporosis
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
Dynamic and Static Balance and the Speed of Reaction in the Elderly
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis
A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis
Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.
The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)